EP1546310A4 - Immunomodulating compositions, processes for their production and uses therefor - Google Patents

Immunomodulating compositions, processes for their production and uses therefor

Info

Publication number
EP1546310A4
EP1546310A4 EP03783854A EP03783854A EP1546310A4 EP 1546310 A4 EP1546310 A4 EP 1546310A4 EP 03783854 A EP03783854 A EP 03783854A EP 03783854 A EP03783854 A EP 03783854A EP 1546310 A4 EP1546310 A4 EP 1546310A4
Authority
EP
European Patent Office
Prior art keywords
processes
production
uses therefor
immunomodulating compositions
immunomodulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03783854A
Other languages
German (de)
French (fr)
Other versions
EP1546310A2 (en
Inventor
Ranjeny Thomas
Brendan John O'sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of EP1546310A2 publication Critical patent/EP1546310A2/en
Publication of EP1546310A4 publication Critical patent/EP1546310A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03783854A 2002-08-12 2003-08-12 Immunomodulating compositions, processes for their production and uses therefor Withdrawn EP1546310A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40313102P 2002-08-12 2002-08-12
US403131P 2002-08-12
AU2002953094 2002-12-04
AU2002953094A AU2002953094A0 (en) 2002-12-04 2002-12-04 Immunomodulating compositions, processes for their production and uses therefor
PCT/AU2003/001021 WO2004015056A2 (en) 2002-08-12 2003-08-12 Immunomodulating compositions, processes for their production and uses therefor

Publications (2)

Publication Number Publication Date
EP1546310A2 EP1546310A2 (en) 2005-06-29
EP1546310A4 true EP1546310A4 (en) 2006-05-17

Family

ID=29408816

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03783854A Withdrawn EP1546310A4 (en) 2002-08-12 2003-08-12 Immunomodulating compositions, processes for their production and uses therefor

Country Status (4)

Country Link
EP (1) EP1546310A4 (en)
AU (1) AU2002953094A0 (en)
CA (1) CA2494675A1 (en)
WO (1) WO2004015056A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029192A2 (en) * 1999-10-15 2001-04-26 Baylor Research Institute Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
DE102005016234B4 (en) * 2005-04-08 2008-05-15 Tgc Biomics Gmbh Method of introducing exogenous antigen into the MHC I presentation pathway of cells
WO2008043157A1 (en) * 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
CN101646418B (en) * 2006-10-12 2013-07-17 昆士兰大学 Compositions and methods for modulating immune responses
US9975944B2 (en) 2013-03-12 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
CN110923206A (en) * 2018-09-20 2020-03-27 天津贝罗尼生物科技有限公司 Method for preparing antigen presenting cell

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047543A2 (en) * 1999-12-24 2001-07-05 Synovis Limited Activation and inhibition of the immune system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047543A2 (en) * 1999-12-24 2001-07-05 Synovis Limited Activation and inhibition of the immune system

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
GAO J X ET AL: "CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 98, no. 2, October 1999 (1999-10-01), pages 159 - 170, XP000973593, ISSN: 0019-2805 *
HAAS M ET AL: "Effect of proteasome inhibitors on monocytic IkB-alpha and -beta depletion, NF-kB activation and cytokine production", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 63, no. 3, March 1998 (1998-03-01), pages 395 - 404, XP000857509, ISSN: 0741-5400 *
HOLLANDER G A ET AL: "Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 10, 1996, pages 4994 - 4998, XP002347200, ISSN: 0027-8424 *
INTERNAL MEDICINE JOURNAL, vol. 32, no. suppl., 2002, pages A14, ISSN: 1444-0903 *
INTERNAL MEDICINE JOURNAL, vol. 33, no. Suppl, 2003, pages A5, ISSN: 1444-0903 *
INTERNAL MEDICINE JOURNAL, vol. 33, no. suppl, 2003, pages A6, ISSN: 1444-0903 *
INTERNAL MEDICINE JOURNAL., vol. 32, no. Suppl., 2002, pages A3, ISSN: 1444-0903 *
LEE J-I ET AL: "Cyclosporin A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 68, no. 9, 15 November 1999 (1999-11-15), pages 1255 - 1263, XP000984802, ISSN: 0041-1337 *
MARTIN E ET AL.: "Antigen-specific suppression of a primed immune response by dendritic cells: implications for autoimmune immunotherapy", COMBINED SCIENTIFIC MEETING OF THE NEW ZEALAND RHEUMATOLOGY ASSOCIATION AND THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION WITH THE NEW ZEALAND HEALTH PROFESSIONALS IN RHEUMATOLOGY AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION OF AUSTRALIA, 26 May 2002 (2002-05-26), Christchurch, New Zealand, XP002347198 *
MARTIN E ET AL: "Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10.", IMMUNITY, vol. 18, no. 1, January 2003 (2003-01-01), pages 155 - 167, XP002347203, ISSN: 1074-7613 *
MARTIN E ET AL: "Inhibition of RelB function in dendritic cells induces antigen-specific tolerance in vivo", ANNUAL SCIENTIFIC MEETING OF THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION, 27 May 2001 (2001-05-27), Adelaide, South Australia, Australia, XP002347199 *
O'SULLIVAN B J ET AL: "RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11421 - 11426, XP002347201, ISSN: 0027-8424 *
O'SULLIVAN BJ ET AL: "Maturation and function of human dendritic cells can be controlled by RelB", ANNUAL SCIENTIFIC MEETING OF THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION, 27 May 2001 (2001-05-27), Adelaide, South Australia, Australia, XP002372798 *
PENNA G ET AL: "1alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, 2000, pages 2405 - 2411, XP001026351, ISSN: 0022-1767 *
SNAPPER C M ET AL: "B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation of Ig secretion and Ig class switching", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 4, 1996, pages 1537 - 1541, XP002347202, ISSN: 0022-1007 *
THOMPSON A G ET AL: "T cells signaled by NF-kappaB- dendritic cells are sensitized not anergic to subsequent activation", JOURNAL OF IMMUNOLOGY, vol. 173, no. 3, 1 August 2004 (2004-08-01), pages 1671 - 1680, XP002372799, ISSN: 0022-1767 *
THOMPSON AG ET AL: "Keeping T cells at bay: Inhibition of NFkB in dendritic cells", COMBINED SCIENTIFIC MEETING OF THE NEW ZEALAND RHEUMATOLOGY ASSOCIATION AND THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION WITH THE NEW ZEALAND HEALTH PROFESSIONALS IN RHEUMATOLOGY AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION OF AUSTRALIA, 26 May 2002 (2002-05-26), Christchurch, New Zealand, XP002372797 *
YOSHIMURA S ET AL: "Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 31, no. 6, June 2001 (2001-06-01), pages 1883 - 1893, XP002221236, ISSN: 0014-2980 *
ZHOU L ET AL: "Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine", CLINICAL IMMUNOLOGY, ACADEMIC PRESS,, US, vol. 93, no. 3, December 1999 (1999-12-01), pages 232 - 238, XP002277919, ISSN: 1521-6616 *

Also Published As

Publication number Publication date
CA2494675A1 (en) 2004-02-19
AU2002953094A0 (en) 2002-12-19
EP1546310A2 (en) 2005-06-29
WO2004015056A2 (en) 2004-02-19
WO2004015056A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
EP1638993A4 (en) Immunomodulating compositions, uses therefor and processes for their production
HUS1500016I1 (en) Tiacumicin production
GB0210143D0 (en) Process
GB0211789D0 (en) Process
GB0205016D0 (en) Process
EP1482937A4 (en) Novel tyloindicines and related processes, pharmaceutical compositions and methods
GB0204607D0 (en) Process
GB0201505D0 (en) Process
EP1546310A4 (en) Immunomodulating compositions, processes for their production and uses therefor
PL372214A1 (en) Novel process
GB0205014D0 (en) Process
AU2003902875A0 (en) Immunomodulating compositions, uses therefor and processes for their production
GB0201378D0 (en) Process
GB0202563D0 (en) Process
GB0212974D0 (en) Process
GB0210183D0 (en) Process
GB0206655D0 (en) Novel process
GB0229476D0 (en) Novel process
AU2004901589A0 (en) Immunomodulating compositions, uses therefor and processes for their production
GB0203665D0 (en) Process
GB0210185D0 (en) Process
GB0225615D0 (en) Compounds, compositions and processes
GB0222494D0 (en) Compounds,compositions and processes
GB0217637D0 (en) Novel processes
AU2003203368A1 (en) 4,5-substituted-2-formylaminobenzamides and processes for their production and conversion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050301

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060330

17Q First examination report despatched

Effective date: 20061204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070417